



ERYTECH to Participate in Upcoming Virtual Investor Conferences in April

Apr 07, 2021 | Press Releases

ERYTECH to Participate in Upcoming Virtual Investor Conferences in April

Lyon (France) and Cambridge, MA (U.S.), April 7, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will participate in the following conferences in the month of April and engage in select one-on-one investor meetings alongside members of the senior management.

SMALLCAP EVENT®- CF&B Communication – April 14-15, 2021

Gil Beyen, Chief Executive Officer, will participate in one-on-one meetings from 8am to 1pm ET (02:00pm to 07:00pm CEST). For more information about the CF&B Communication's SMALLCAP EVENT, please refer to the CF&B website: <http://small2021.midcapevents.com>

Kempen & Co. Life Sciences Conference - 2021 Thematic Virtual Series – April 28, 2021

Gil Beyen, Chief Executive Officer, Iman El-Hariry, Chief Medical Officer, and Eric Soyer Chief Financial Officer will participate in one-on-one meetings, small group meetings and showcase sessions from 8am to 2pm ET (02:00pm to 08:00pm CEST). For more information about the Kempen & Co Life Sciences Conference Series, please refer to the Kempen conference website: <https://www.kempen.com/en/securities/events/life-sciences-conference>

If you are interested in arranging a one-on-one meeting, please contact your conference representative or contact [Corey Davis](#) at LifeSciAdvisors.

About ERYTECH and eryaspase

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH's primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company's lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells' altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial in acute lymphoblastic leukemia recently reported positive results.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

For more information, please visit www.erytech.com

Forward-looking information

This press release contains forward-looking statements including but not limited to statements with respect to the clinical development plans of eryaspase; the clinical trials of the Company's product candidates, including the timeline for patient enrollment as well as expected timing of the availability of results and interim superiority analysis; potential impacts of the ongoing coronavirus (COVID-19) pandemic on the Company's clinical trials, including TRYbeCA-1 clinical trial; the possible sales of ADSs pursuant to the ATM program; and the Company's anticipated cash runway as extended by its convertible bond financing and ATM facility. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results and timeline may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Further description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French *Autorité des Marchés Financiers* (AMF), the Company's Securities and Exchange Commission (SEC) filings and reports, including in the Company's 2019 *Document d'Enregistrement Universel* filed with the AMF on March 18, 2020 and in the Company's Annual Report on Form 20-F filed with the SEC on March 18, 2020 and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law. In addition, the COVID-19 pandemic and the associated containment efforts have had a serious adverse impact on the economy, the severity and duration of which are uncertain. Government stabilization efforts will only partially mitigate the consequences. The extent and duration of the impact on the Company's business and operations is highly uncertain, and that impact includes effects on its clinical trial operations and supply chain. Factors that will influence the impact on the Company's business and operations include the duration and extent of the pandemic, the extent of imposed or recommended containment and mitigation measures, and the general economic consequences of the pandemic.

The pandemic could have a material adverse impact on the Company's business, operations and financial results for an extended period of time.

CONTACTS

ERYTECH
Eric Soyer
CFO & COO

LifeSci Advisors, LLC
Investor Relations
Corey Davis, Ph.D.

NewCap
Mathilde Bohin /
Louis-Victor Delouvrier
Investor relations
Nicolas Merigeau
Media relations

-

+33 4 78 74 44 38
investors@ERYTECH.com

-

+1 (212) 915 - 2577
cdavis@lifesciadvisors.com

-

+33 1 44 71 94 94
ERYTECH@newcap.eu

Attachment

- [ERYTECH PR 2021 April Conference curtain raiser EN vf](#)